Personalis (NASDAQ:PSNL) Sets New 1-Year High – What’s Next?

Shares of Personalis, Inc. (NASDAQ:PSNL) reached a new 52-week high during trading on Tuesday . The stock traded as high as $16.15 and last traded at $15.04, with a volume of 10664380 shares traded. The stock had previously closed at $14.07.

Wall Street Analyst Weigh In

PSNL has been the topic of a number of recent analyst reports. BTIG Research reduced their price target on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Morgan Stanley raised their price target on Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.67.

Personalis Stock Performance

The company has a market capitalization of $1.57 billion, a PE ratio of -14.75 and a beta of 2.24. The business has a fifty day moving average price of $10.18 and a 200 day moving average price of $8.70.

Personalis (NASDAQ:PSNL) last issued its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The firm had revenue of $15.47 million for the quarter, compared to analysts’ expectations of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. Research analysts forecast that Personalis, Inc. will post -1.07 earnings per share for the current fiscal year.

Insider Activity at Personalis

In other news, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total value of $1,508,000.00. Following the transaction, the chief executive officer owned 235,986 shares of the company’s stock, valued at approximately $3,558,668.88. This trade represents a 29.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $14.00, for a total transaction of $69,748.00. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at approximately $2,783,662. This represents a 2.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 435,032 shares of company stock valued at $5,599,929. 4.20% of the stock is owned by insiders.

Institutional Trading of Personalis

Large investors have recently added to or reduced their stakes in the stock. Aberdeen Group plc lifted its stake in shares of Personalis by 36.1% during the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after purchasing an additional 861,948 shares in the last quarter. Oracle Investment Management Inc. acquired a new stake in shares of Personalis in the third quarter valued at about $1,496,000. Howland Capital Management LLC grew its stake in shares of Personalis by 65.5% in the fourth quarter. Howland Capital Management LLC now owns 547,115 shares of the company’s stock valued at $4,355,000 after buying an additional 216,442 shares in the last quarter. Next Century Growth Investors LLC purchased a new stake in shares of Personalis during the 4th quarter valued at about $4,970,000. Finally, D.A. Davidson & CO. purchased a new stake in shares of Personalis during the 4th quarter valued at about $1,158,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.